Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EPS (Weighted Average and Diluted) (2022 - 2025)

Vivos Therapeutics has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.58 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 107.14% to -$0.58 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.07 through Dec 2025, up 28.87% year-over-year, with the annual reading at -$2.07 for FY2025, 6.76% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.58 for Q4 2025 at Vivos Therapeutics, down from -$0.49 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.28 in Q4 2024 and troughed at -$6.4 in Q3 2022.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.6 (2024), against an average of -$1.86.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 1300.0% in 2023 and then skyrocketed 90.82% in 2024.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$5.0 in 2022, then surged by 39.0% to -$3.05 in 2023, then skyrocketed by 90.82% to -$0.28 in 2024, then crashed by 107.14% to -$0.58 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EPS (Weighted Average and Diluted) are -$0.58 (Q4 2025), -$0.49 (Q3 2025), and -$0.55 (Q2 2025).